Novartis reports final data of ALIGN trial in IgAN
A total of 340 biopsy-confirmed IgAN patients were randomised to daily oral Vanrafia or a placebo for approximately 132 weeks.
News
Lyell doses first patient in Phase III trial for LBCL
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial
BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD
Veradermics concludes enrolment in second Phase III VDPHL01 trial
Genentech reports fenebrutinib Phase III results for PPMS
TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial
Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy
